PROGRAM

12 Conference Central European Hepatologic Collaboration, Gdańsk, 24 September 2023
Radisson Hotel & Suites Gdańsk
80-748 Gdańsk, ul. Chmielna 10, Poland

8:30-8:50 Opening and inaugural lecture

1. Opening – Robert Flisiak (Białystok, Poland)
2. HBV meets the musical genius. Can it inspire novel research in hepatitis B patients? – Piotr Rzymski (Poznań, Poland)

8:50-9:50 Steatotic liver disease – renamed disease – Krzysztof Simon, Jan Sperl

1. Alcohol associsted liver disease spectrum - our right and left turns – Lubomir Skladany (Banska Brystrica, Slovakia)
2. Impact of non-alcoholic fatty liver disease on clinical outcomes in patients with Covid-19 – Adriana Vince (Zagreb, Croatia)
3. Association of sarcopenia and NAFLD - Ivana Mikolasevic (Rijeka, Croatia)

Discussion (15 min)

9:50-10:50 Gut and the liver – Michał Kukla, Ivica Grgurevic

1. Gut metagenome analysis in severe alcohol associated hepatitis: a cohort study - Katarina Soltys, Lubomir Skladany (Banska Brystrica, Slovakia)
2. Circulating microbiome in patients with liver cirrhosis – Rolandas Gedgaudas (Kaunas, Lithuania)
3. Fecal calprotectin levels in decompensated advanced chronic liver diseases, do we need to measure? - Tomas Koller (Bratislava, Slovakia)

Discussion (15 min)

10:50-11:05 Coffee break

11:05-12:50 Viral hepatitis – Małgorzata Pawłowska, Adriana Vince

1. The most difficult to cure with pangenotypic regimens HCV infected population – Robert Flisiak (Białystok, Poland)
2. Does a positive HCV RNA result at the end of DAA therapy herald the ineffectiveness of the treatment? – Dorota Zarębska-Michaluk (Kielce, Poland)
3. A model for detection and linkage to care of HCV infected persons in Croatian prisons - Lucija Virovic Jukic (Zagreb, Croatia)
4. Hepatitis C screening and elimination program in Lithuania: the first year results – Limas Kupčinskas (Kaunas, Lithuania)
5. The significance of hepatitis delta in Central Europe – Jerzy Jaroszewicz (Bytom, Poland)
6. Epidemiology of hepatitis E in Croatia - Anna Mrzljak (Zagreb, Croatia)

Discussion (15 min)

12:50-14:05 Liver transplantation and hepatic surgery – Piotr Małkowski, Pavel Trunecka

1. How do we prepare cirrhotic patients to surgery? – Michał Kukla (Kraków, Poland)
2. Liver transplantation in primary sclerosing cholangitis - can we do better? - Tajana Filipec Kanizaj (Zagreb, Croatia)
3. Porphyrias as an indication for liver transplantation - Jan Sperl (Prague, Czech Rep.)
4. Fatty liver disease after liver transplantation - Pavel Trunecka (Prague, Czech Rep.)

Discussion (15 min)

14:05-15:00 Lunch break

15:00-16:15 Hepatocellular carcinoma – Jerzy Jaroszewicz, Bela Hunyady

1. Subclinical inflammation predicts prognosis in hepatocellular cancer - Peter Jarcuska (Kosice, Slovakia)
2. Time for personalised screening of HCC? – Sona Frankova (Prague, Czech Rep.)
3. Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models – Piotr Małkowski (Warszawa, Poland)
4. Chemerine and betatrofine level in patients with HCC-diagnostic value - Monika Pazgan-Simon, Joanna Górka-Dynysiewicz, Krzysztof Simon (Wrocław, Poland)

Discussion (15 min)

16:15-16:30 Coffree break

16:30-18:00 Diagnostic and therapeutic issues related to chronic liver diseases – Dorota Zarębska-Michaluk, Peter Jarcuska

1. Cases of acute or acute-on-chronic liver failure – Bela Hunyady (Pecs, Hungary)
2. Biomarkers of portal hypertension in compensated advanced chronic liver disease - Ivica Grgurevic (Zagreb, Croatia)
3. Do we need second line treatment in primary biliary cholangitis? - Sylvia Drazilova (Kosice, Slovakia)
4. Hepatic alveolar echinococcosis in Poland - current problems of epidemiology, diagnosis and treatment – Katarzyna Sikorska (Gdynia, Poland)
5. Cigarette smoking and liver fibrosis - Gabriella Par (Pecs, Hungary)

Discussion (15 min)

18:00 Summary and end of the conference – Robert Flisiak (Białystok, Poland)